|
시장보고서
상품코드
1766592
축성 척추관절염 시장 : 유형별, 치료제별, 투여 경로별, 제품 유형별, 성별, 유통 채널별, 최종사용자별, 지역별Axial Spondyloarthritis Market, By Type, By Therapeutics, By Route of Administration, By Product Type, By Gender, By Distribution Channel, By End User, By Geography |
||||||
축성 척추관절염 시장은 2025년에 44억 1,000만 달러로 추정되며, 2032년에는 70억 1,000만 달러에 달할 것으로 예측되며, 2025년부터 2032년까지 CAGR 6.85%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 44억 1,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2025-2032년 |
| 예측 기간 : 2025-2032년 CAGR | 6.85% | 2032년 가치 예측 | 70억 1,000만 달러 |
축성 척추관절염(axSpA)은 주로 척추와 천장관절에 영향을 미치는 만성 염증성 류마티스 질환으로, 진행성 구조적 손상, 기능 장애 및 환자의 삶의 질에 심각한 영향을 미치는 것이 특징입니다. 세계 축성 척추관절염 시장은 전 세계 수백만 명이 앓고 있는 이 쇠약해지는 질환을 해결하기 위해 고안된 치료 중재, 진단 도구, 관리 솔루션의 종합적인 스펙트럼을 포괄합니다. 이 시장에는 X-선 촬영 강직성 척추염(AS)과 비X-선 촬영 액와부 척추관절염(nr-axSpA)이 모두 포함되며, 질환의 분류와 진행에 대한 이해의 진전을 반영하고 있습니다. 의료 전문가와 환자들의 인식이 높아진 데다 조기 진단과 표적 생물학적 제제의 발전으로 인해 이 시장은 상당한 성장세를 보이고 있습니다.
종양괴사인자(TNF) 억제제, 인터류킨-17(IL-17) 억제제, 그리고 새로운 야누스 키나아제(JAK) 억제제 등이 치료의 주류를 이루고 있으며, 환자들에게 증상 관리 개선과 질병 개선의 가능성을 제공하고 있습니다. 의료비 지출 증가, 자가면역질환의 유병률 증가, 첨단 영상 진단 기술을 통한 진단 능력 향상, 강력한 의약품 연구개발 활동으로 인해 세계 축성척추관절염 시장은 광범위한 류마티스 치료제 산업에서 중요한 부문으로 자리매김하고 있습니다.
시장 역학
축성 척추관절염 세계 시장은 시장 성장 전망과 치료 발전의 기회를 높이는 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 특히 20-40대 젊은 층의 질병 유병률 증가는 전 세계 인구의 0.7%가 축성척추관절염을 앓고 있는 것으로 추정되는 가운데 효과적인 치료 솔루션에 대한 큰 수요를 창출하며 시장 성장의 주요 촉매제가 되고 있습니다. 자기공명영상(MRI) 및 특수 바이오마커를 포함한 첨단 영상 진단 기술을 통한 인식과 진단 능력의 향상으로 질병의 조기 발견과 개입이 가능해져 치료 가능한 환자군을 크게 확대할 수 있게 되었습니다. 혁신적인 생물학적 제제 및 표적화된 합성 질환 조절 항류마티스제제(tsDMARDs)의 강력한 파이프라인은 치료 효과의 향상과 개별화된 치료 접근법을 제공하고, 합리적인 가격 책정 및 환자 결과 개선을 통해 시장 확대를 주도하고 있습니다.
그러나 생물학적 제제의 치료비는 환자 1인당 연간 5만 달러가 넘을 수 있어 가격에 민감한 시장에서의 사용이 제한되고, 전 세계 헬스케어 시스템에 상환 문제를 야기하는 등 시장 성장을 저해하는 요인으로 작용하고 있습니다. 신약에 대한 엄격한 승인 절차는 대규모 임상시험 요건과 함께 개발 기간이 길어지고 개발 비용이 증가하여 신흥 치료제의 시장 진입을 저해할 수 있습니다. 또한, axSPA의 진단은 복잡하고, 종종 오진이나 진단 지연이 발생하여 적시에 치료를 시작하거나 시장 침투에 장애가 되고 있습니다. 그럼에도 불구하고, 신흥국의 의료 인프라 확대, 의료비 지출 증가, 브랜드 바이오의약품을 대체할 수 있는 비용 효율적인 바이오시밀러 의약품의 수용 확대는 선진 치료 접근성을 민주화하고 다양한 지역과 경제 부문에 걸쳐 시장을 확대할 것으로 예상됨에 따라 큰 비즈니스 기회를 창출하고 있습니다.
본 조사의 주요 특징
- 세계의 축성 척추관절염 시장을 상세히 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년)의 시장 규모(10억 달러)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 인사이트를 제공합니다.
- 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략 등의 매개 변수를 기반으로 세계 축성 척추관절염 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 축성 척추관절염 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
- 조사 목적
- 가정
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매/승인
- PEST 분석
- PORTER의 분석
- 인수합병 시나리오
- 업계 동향
제4장 세계의 축성 척추관절염 시장, 유형별, 2020-2032년
- 강직성 척추염
- 비X선학적 축성 척추관절염
제5장 세계의 축성 척추관절염 시장, 치료제별, 2020-2032년
- 비스테로이드성 항염증제(NSAID)
- 생물학적 질환 변성 항류마티스제(bDMARD)
- 기존 DMARD
- 기타(코르티코스테로이드 등)
제6장 세계의 축성 척추관절염 시장, 투여 경로별, 2020-2032년
- 경구
- 피하주사(SC)
- 정맥내(IV) 주입
제7장 세계의 축성 척추관절염 시장, 제품 유형별, 2020-2032년
- 브랜드
- 제네릭
제8장 세계의 축성 척추관절염 시장, 성별, 2020-2032년
- 여성
- 남성
제9장 세계의 축성 척추관절염 시장, 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제10장 세계의 축성 척추관절염 시장, 최종사용자별, 2020-2032년
- 병원
- 전문 클리닉
- 외래 수술 센터
- 재활 및 물리치료 센터
- 기타(학술조사기관 등)
제11장 세계의 축성 척추관절염 시장, 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제12장 경쟁 구도
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Eli Lilly and Company
- Merck & Co.
- Gilead Sciences
- Sanofi
- Takeda
- Biogen
- Astellas Pharma
제13장 애널리스트의 추천사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제14장 참고문헌과 조사 방법
- 참고문헌
- 조사 방법
- 출판사 소개
Axial Spondyloarthritis Market is estimated to be valued at USD 4.41 Bn in 2025 and is expected to reach USD 7.01 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.85% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.41 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.85% | 2032 Value Projection: | USD 7.01 Bn |
Axial Spondyloarthritis (axSpA) represents a chronic inflammatory rheumatic disease primarily affecting the spine and sacroiliac joints, characterized by progressive structural damage, functional impairment, and significant impact on patients' quality of life. The global axial spondyloarthritis market encompasses a comprehensive spectrum of therapeutic interventions, diagnostic tools, and management solutions designed to address this debilitating condition that affects millions worldwide. The market includes both ankylosing spondylitis (AS), the radiographic form, and non-radiographic axial spondyloarthritis (nr-axSpA), reflecting the evolving understanding of disease classification and progression. With increasing awareness among healthcare professionals and patients, coupled with advancements in early diagnosis and targeted biologics, the market has witnessed substantial growth momentum.
The therapeutic landscape is dominated by tumor necrosis factor (TNF) inhibitors, interleukin-17 (IL-17) inhibitors, and emerging Janus kinase (JAK) inhibitors, offering patients improved symptom management and disease modification potential. Rising healthcare expenditure, growing prevalence of autoimmune disorders, enhanced diagnostic capabilities through advanced imaging techniques, and robust pharmaceutical research and development activities are collectively driving market expansion, positioning the global axial spondyloarthritis market as a critical segment within the broader rheumatology therapeutics industry.
Market Dynamics
The global axial spondyloarthritis market is propelled by several compelling drivers that collectively enhance market growth prospects and therapeutic advancement opportunities. Increasing disease prevalence, particularly among young adults aged 20-40 years, serves as a primary growth catalyst, with an estimated 0.7% of the global population affected by axSpA, creating substantial demand for effective treatment solutions. Growing awareness and improved diagnostic capabilities through advanced imaging technologies, including magnetic resonance imaging (MRI) and specialized biomarkers, enable earlier disease detection and intervention, expanding the treatable patient population significantly. The robust pipeline of innovative biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) offers enhanced therapeutic efficacy and personalized treatment approaches, driving market expansion through premium pricing and improved patient outcomes.
However, market growth faces notable restraints including high treatment costs associated with biologic therapies, which can exceed USD 50,000 annually per patient, limiting accessibility in price-sensitive markets and creating reimbursement challenges for healthcare systems globally. Stringent regulatory approval processes for new therapeutic agents, coupled with extensive clinical trial requirements, result in prolonged development timelines and increased development costs, potentially hindering market entry for emerging treatments. Additionally, the complex nature of axSpA diagnosis, often involving years of misdiagnosis or delayed diagnosis, creates barriers to timely treatment initiation and market penetration. Nevertheless, significant opportunities emerge through expanding healthcare infrastructure in developing economies, increasing healthcare spending, and growing acceptance of biosimilar medications that offer cost-effective alternatives to branded biologics, potentially democratizing access to advanced treatments and expanding market reach across diverse geographic regions and economic segments.
Key Features of the Study
- This report provides in-depth analysis of the global axial spondyloarthritis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global axial spondyloarthritis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie, Amgen, Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, Roche, UCB, Eli Lilly and Company, Merck & Co., Gilead Sciences, Sanofi, Takeda, Biogen, and Astellas Pharma
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global axial spondyloarthritis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global axial spondyloarthritis market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis
- Therapeutics Insights (Revenue, USD Bn, 2020 - 2032)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- Conventional DMARDs
- Sulfasalazine
- Methotrexate
- Others (Corticosteroids, etc.)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Subcutaneous (SC) Injections
- Intravenous (IV) Infusions
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Female
- Male
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Rehabilitation & physiotherapy centers
- Others (Academic and Research Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie
- Amgen
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Roche
- UCB
- Eli Lilly and Company
- Merck & Co.
- Gilead Sciences
- Sanofi
- Takeda
- Biogen
- Astellas Pharma
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Axial Spondyloarthritis Market, By Type
- Global Axial Spondyloarthritis Market, By Therapeutics
- Global Axial Spondyloarthritis Market, By Route of Administration
- Global Axial Spondyloarthritis Market, By Product Type
- Global Axial Spondyloarthritis Market, By Gender
- Global Axial Spondyloarthritis Market, By Distribution Channel
- Global Axial Spondyloarthritis Market, By End User
- Global Axial Spondyloarthritis Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Axial Spondyloarthritis Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Non-radiographic Axial Spondyloarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Axial Spondyloarthritis Market, By Therapeutics, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Meloxicam
- Naproxen
- Celecoxib
- Diclofenac
- Others (Indomethacin, etc.)
- Meloxicam
- Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- TNF inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Others (Golimumab, etc.)
- IL-17 inhibitors
- Secukinumab
- Ixekizumab
- Others (Bimekizumab, etc.)
- JAK inhibitors
- Tofacitinib
- Upadacitinib
- TNF inhibitors
- Conventional DMARDs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sulfasalazine
- Methotrexate
- Sulfasalazine
- Others (Corticosteroids, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Axial Spondyloarthritis Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous (SC) Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous (IV) Infusions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Axial Spondyloarthritis Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Axial Spondyloarthritis Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Axial Spondyloarthritis Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Axial Spondyloarthritis Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Rehabilitation & physiotherapy centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Academic and Research Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Axial Spondyloarthritis Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
